Arkolith/Insider Trading/KNSA/Form 4

Malley Thomas

DirectorKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Jun 2, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 29, 2026Option exercise(M)3K——15K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 29, 2026Grant(A)12K—$012K
May 29, 2026Grant(A)2K—$02K
May 29, 2026Option exercise(M)3K—$00

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001403322-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Kiniksa Pharmaceuticals International, plc

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Form 4 insider API

Open-market buys and sells, cluster scans, company flows.

insider.transactions

13F holdings API

Owners, holdings, deltas, point-in-time portfolios.

stock.owners

MCP quickstart

Connect an agent, mint a key, make the first call.

/api/mcp